PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20482961-8 2010 In summary, budesonide/formoterol pMDI is an effective, well-tolerated treatment option for patients with persistent asthma for whom ICS/long-acting beta2-adrenergic agonist combination therapy is appropriate. Budesonide 12-22 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 149-154 19644045-3 2009 OBJECTIVES: To assess the efficacy and tolerability of budesonide/formoterol added to tiotropium in patients eligible for inhaled corticosteroid/long-acting beta(2)-agonist combination therapy. Budesonide 55-65 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 157-163 20477290-1 2008 Budesonide/formoterol is a combination of an inhaled corticosteroid plus a long-acting beta(2)-agonist available as a dry-powder inhaler for the indication of asthma and chronic obstructive pulmonary disease in various countries outside of the USA and as a pressurized metered-dose inhaler in the USA for the indication of asthma. Budesonide 0-10 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 87-93 17329493-1 2007 Clinical trials have recently demonstrated that using a budesonide/formoterol combination inhaler as regular maintenance treatment twice daily but also as a rescue therapy for breakthrough symptoms can provide more effective control of asthma, particularly in reducing exacerbations, than using a short-acting beta2-agonist or formoterol as rescue therapy. Budesonide 56-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 310-315 16573703-8 2006 Children receiving budesonide also needed significantly less intervention with other inhaled corticosteroids (12.3% vs. 22.5% over 3 yrs; p < 0.01), with trends towards decreased usage of oral/systemic corticosteroids and inhaled short-acting beta2-agonists. Budesonide 19-29 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 246-251 16433920-10 2006 CONCLUSION: Budesonide/formoterol and formoterol provided similarly rapid relief of acute bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-acting beta2-agonist. Budesonide 12-22 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 190-195 18044091-6 2006 However, when patients with more severe COPD were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rates compared with the use of a long-acting beta2-agonist alone. Budesonide 81-91 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 210-215 15502112-3 2005 We hypothesized that in patients receiving low maintenance dose budesonide/formoterol (bud/form), replacing short-acting beta2-agonist (SABA) reliever with as-needed bud/form would provide rapid symptom relief and simultaneous adjustment in antiinflammatory therapy, thereby reducing exacerbations. Budesonide 64-74 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 121-126 12570112-8 2003 Budesonide/formoterol decreased all symptom scores and use of reliever beta2-agonists significantly versus placebo and budesonide, and improved HRQL versus placebo. Budesonide 0-10 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 71-76 14969576-1 2004 Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol, and is inhaled via the Turbuhaler device. Budesonide 0-10 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 103-108 14520851-4 2003 Budesonide reduced frequency of acute asthma episodes and the need in inhalations of short-acting beta 2-agonists. Budesonide 0-10 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 98-104 14720060-4 2002 Concomitant administration of montelukast (5 mg/day) and inhaled budesonide (200 microg twice daily) resulted in a trend towards an increase in FEV1 (p=0.06, primary endpoint) and a statistically significant reduction in both as-needed beta2-agonist usage and the percentage of days with asthma exacerbations compared with budesonide plus placebo. Budesonide 65-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 236-241 11421509-10 2001 In conclusion, adding the inhaled, long-acting beta2-agonist formoterol to low-moderate doses of the inhaled corticosteroid budesonide generated significant gains in all outcome measures with partial or complete offset of costs. Budesonide 124-134 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 47-52 11129126-2 2000 In infants and young children with persistent asthma, day- and night-time symptom scores, and the number of days in which beta2-agonist bronchodilators were required, were significantly lower during randomised, double-blind treatment with budesonide inhalation suspension 0.5 to 2 mg/day than placebo in 3 multicentre trials. Budesonide 239-249 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 122-127 11289332-10 2001 CONCLUSIONS: Short-term high-dose budesonide therapy can be considered an alternative for children who are experiencing an acute asthma attack that is unresponsive to home management with regular use of an inhaled beta2 mimetic, yet who are not severe enough to hospitalize. Budesonide 34-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 214-219 11217872-1 2001 Current evidence suggests that the addition of the long acting inhaled beta2-agonist formoterol to low or moderate doses of the inhaled corticosteroid budesonide is effective in improving lung function and reducing the incidence of asthma exacerbations. Budesonide 151-161 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 71-76 10367823-13 1999 Fewer beta2-agonist activations were used at the end of the trial by patients receiving budesonide (2.4/d vs 4.2/d; P=.01). Budesonide 88-98 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 6-11 10095821-8 1999 RESULTS: Following administration of 800 micrograms day-1 of inhaled budesonide, there was an increase in the mean FEV1 from 1.40 +/- 0.20 to 1.92 +/- 0.22 L (P < 0.001) and a significant decrease in inhaled beta 2 agonist consumption in group A. Budesonide 69-79 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 211-217 9864001-9 1998 In conclusion inhaled budesonide can lead to improvements in noninvasive markers of airway inflammation, in association with a small improvement in lung function, even in mildly asthmatic patients who require an inhaled beta2-agonist less than once daily. Budesonide 22-32 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 220-225 9627589-4 1998 RESULTS: Patients in each of the three budesonide treatment groups showed significant dose-related improvements in lung function (morning peak expiratory flow and FEV1), in asthma symptoms, and with a significant decrease in inhaled beta 2-agonist use in comparison with placebo. Budesonide 39-49 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 233-239 7497762-6 1995 In six of eight "responders to beta 2-agonist," there was a significant improvement in the FEV1 (defined as > or = 20%) following inhaled budesonide, as compared with placebo. Budesonide 141-151 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 31-37 7741186-5 1995 Significantly fewer sleep disturbances and fewer nighttime inhalations of beta 2-agonists were required during budesonide and combination therapy than theophylline treatment. Budesonide 111-121 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 74-80 2520343-10 1989 During treatment with budesonide only a significant correlation of beta 2-agonist use with PC20 histamine remained. Budesonide 22-32 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 67-73 7822661-5 1995 RESULTS: One hundred micrograms of budesonide per day markedly improved symptoms, morning and evening peak expiratory flow rates, and use of rescue beta 2-agonists (p < 0.01). Budesonide 35-45 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 148-154 2062329-8 1991 Budesonide was also more effective in reducing the symptoms of asthma (P less than 0.01) and the use of supplemental beta 2-agonist medication (P less than 0.01). Budesonide 0-10 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 117-123 31112386-1 2019 BACKGROUND: In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting beta2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. Budesonide 56-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 200-205 30368448-1 2018 OBJECTIVES: Budesonide/formoterol (BF) Spiromax is an inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). Budesonide 12-22 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 91-96 30306750-13 2018 CONCLUSIONS: EDN is a useful relatively non-invasive biomarker for predicting responses to montelukast and budesonide treatment of preschool children with beta2-agonist responsive recurrent wheeze and multiple-trigger wheeze (Trial registry at UMIN Clinical Trials Registry, UMIN000008335). Budesonide 107-117 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 155-160 29773947-1 2018 Purpose: This study investigated the efficacy, safety, and pharmacokinetics of the inhaled corticosteroid/long-acting beta2-agonist fixed-dose combination budesonide/formoterol fumarate (BFF) metered dose inhaler (MDI), compared with the monocomponents budesonide (BD) MDI and formoterol fumarate (FF) MDI, in patients with moderate-to-severe COPD. Budesonide 155-165 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 118-123 22035853-7 2012 A combination of an inhaled corticosteroid and a long-acting beta-2 agonist was the reported therapy by 56.0% of patients, with the rate of controlled asthma and improved quality of life being higher in patients on extrafine beclomethasone/formoterol compared to budesonide/formoterol (p<0.05) and fluticasone/salmeterol (p<0.05 for quality of life). Budesonide 263-273 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 61-67 24341818-4 2014 This review found that administration of beta2-agonist bronchodilators via dry powder inhalers (formoterol, salbutamol, terbutaline and budesonide/formoterol) was effective during severe asthma worsening and acute asthma attacks, and was as effective as established therapies with a pressurized metered-dose inhaler with or without a spacer, or nebulization. Budesonide 136-146 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 41-46 21778259-4 2012 RESULTS: The study group receiving a formoterol-budesonide combined treatment showed a significant improvement, both clinically and statistically, of symptoms (dyspnea, number of coughs, and rescue beta(2)-adrenergic agonist-free days). Budesonide 48-58 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 198-204